Targeted Therapeutics in Oncology and Neurology: Advances in Kinase Inhibition and Biomarkers for Brain Injury.

Innovations in pharmaceutical science drive new treatment approaches for cancer and brain injury. This Patent Highlight reviews findings from three patents focused on kinase inhibition in cancer therapy and using biomarkers to assess brain injury. By targeting key enzymes such as AKT1 and diacylglycerol kinase alpha (DGKα), these innovations offer new strategies for cancer treatment, particularly in cases of resistance to conventional therapies. In parallel, advances in biomarker-based diagnostics provide a more sensitive means of detecting traumatic brain injuries (TBI). Together, these breakthroughs hold promise for improving outcomes in oncology and neurology.